View Clinical Trial (Medical Research Study)
A Pilot Randomized Trial to Determine the Efficacy of a Probiotic, Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA)
| City: |
|
Madison |
| State: |
|
Wisconsin |
| Zip Code: |
|
53792 |
| Conditions: |
|
Infection |
| Purpose: |
|
The purpose of this study is to investigate the feasibility, safety and efficacy of oral
probiotic, Lactobacillus rhamnosus versus oral placebo for reducing colonization by MRSA.
|
| Study Summary: |
|
Healthcare-associated infections are an important threat to patient safety. Currently,
between 5 and 10 percent of patients admitted to acute care hospitals acquire one or more
infections; healthcare-associated infections affect approximately 2 million patients each
year in the United States, result in 90,000 deaths, and are associated with an added cost of
$4.5 to $5.7 billion per year. Seventy percent of healthcare-associated infections are
caused by antimicrobial resistant bacteria, such as methicillin-resistant Staphylococcus
aureus (MRSA), resulting in increased antimicrobial usage, morbidity and mortality, making
prevention of multiresistant bacteria essential.
Eradication of colonization has been shown to greatly reduce infection; however, there are
no reliable means of providing sustained eradication of colonization. No effective means of
eradicating MRSA colonization exist.
Probiotics containing strains of lactobacilli represent a novel approach to the prevention
and control of antimicrobial resistance and have been studied extensively for a variety of
infections. Even though various studies have shown probiotics to be effective for prevention
of vaginal infections, urinary tract infections, etc no studies have examined the potential
of probiotics to eradicate colonization by resistant pathogens, such as MRSA.
|
| Criteria: |
|
Inclusion Criteria:
- subjects will be male or female
- 18 years of age or older
- may or may not be hospitalized
- able to take oral medications
- have been found to be colonized with MRSA or at high risk of being colonized by
MRSA and are not taking antibiotics
Exclusion Criteria:
- people on antibiotics will not be eligible to participate
|
| NCT ID: |
|
NCT01112995 |
| Primary Contact: |
|
Principal Investigator
Nasia Safdar, MD, Ph.D
University of Wisconsin Department of Medicine (Infectious Disease)
Nasia Safdar, MD, Ph.D
Phone: (608)263-1545
Email: ns2@medicine.wisc.edu
|
| Backup Contact: |
|
Email: ppanjikar@medicine.wisc.edu
Prerna Panjikar, BS
Phone: (608)262-4549
|
| Location Contact: |
|
Madison, Wisconsin 53792
United States
Nasia Safdar, MD, Ph.D
Phone: 608-265-9790
Email: ns2@medicine.wisc.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|